On October 26th 2023, the pharmaceutical company Biohaven submitted an application for a new drug approval of Troriluzole to the European Medicines Agency (EMA) for the treatment of Spinocerebellar Ataxia Type-3 (SCA3). This is being reviewed by the EMA’s Committee for Medicinal Products for Human Use (CHMP), the regulatory body that makes recommendations on new drug approvals in the EU.
Ataxia UK is providing evidence to the EMA about the burden of illness in SCA3 via our role within Euro-ataxia. We will update you on its progress through our communications. You can read about the application on the EMA website here.
To read more about Troriluzole for the treatment of SCA3, you can read our previous article on the topic here.